[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BPharmCatalyst BioPharmCatalyst

BioPharmCatalyst posts on X about watchlist, $tnxp, $otlk, $clsd the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXXXXX engagements in the last XX hours.

Engagements: XXXXXX #

X Week XXXXXXX +63%
X Month XXXXXXX +96%
X Months XXXXXXX +58%
X Year XXXXXXXXX -XX%

Mentions: XX #

X Week XX -XX%
X Month XX no change
X Months XXX +22%
X Year XXX +76%

Followers: XXXXXX #

X Week XXXXXX +0.29%
X Month XXXXXX +0.97%
X Months XXXXXX +2.30%
X Year XXXXXX +4.40%

CreatorRank: XXXXXXX #

Social Influence #

Social category influence cryptocurrencies #4446 finance stocks countries

Social topic influence watchlist, $tnxp, $otlk, $clsd, $srpt, $rptx #1, $grph, $vnda, $fbio, $rgnx

Top assets mentioned Sarepta Therapeutics, Inc. (SRPT) Cytokinetics Inc. (CYTK) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Arrowhead Research Corporation (ARWR) Curate (XCUR) Iovance Biotherapeutics, Inc. Common Stock (IOVA) Amicus Therapeutics, Inc (FOLD) Hooked Protocol (HOOK) apM Coin (APM) Apellis Pharmaceuticals, Inc. Common Stock (APLS) Novo-Nordisk (NVO) NEO (NEO) ATAI Life Sciences (ATAI) SuperRare (RARE) Pfizer, Inc. (PFE)

Top Social Posts #

Top posts by engagements in the last XX hours

"BioPharmCatalyst Weekly #Watchlist Key PDUFA and Regulatory Catalysts for the Next X Months $OMER $ABEO $RGNX $FBIO $CYTK $VNDA $OTLK $IONS $ARWR $TNXP $GRPH"
@BPharmCatalyst on X 2025-07-14 13:17:37 UTC 29.9K followers, 7440 engagements

"🎧 New Episode Alert On Biotech Bulls and Breakthroughs John Gagliano and Sheff break down: 🔹 Key biotech market trends 🔹 Catalyst-driven trading strategies 🔹 Small-cap opportunities"
@BPharmCatalyst on X 2025-07-14 11:38:00 UTC 29.9K followers, 383.6K engagements

"$CLSD announced that Health Canada has granted approval for XIPERE for suprachoroidal use in the treatment of uveitic macular edema (UME). See More Biotech Updates👇 $ABVX $ANEB $CLSD $IMNN $GHRS $PHVS $IOVA $LTRN"
@BPharmCatalyst on X 2025-07-23 20:41:33 UTC 29.9K followers, 5936 engagements

"$ABVX shares are halted following results that its 50mg obefazimod achieved XXXX% pooled placebo-adjusted clinical remission at X weeks in Phase X ABTECT induction trials for moderate-to-severe UC meeting all key secondary endpoints with favorable safety. Maintenance data is due 2Q 2026 ahead of planned NDA/MAA submissions in 2H 2026. The company also delayed 1H 2025 financial results from August XX to September X 2025. Preliminary cash and cash equivalents as of June XX 2025 were approximately $XXXX million (unaudited). See More Biotech Updates👇 $IOVA $REPL $PMN $QNTM $STRO $AMIX $ABVX"
@BPharmCatalyst on X 2025-07-22 20:51:45 UTC 29.9K followers, 4304 engagements

"$CLSD initiated a strategic review to explore options including asset sales partnerships or M&A to advance its SCS platform; Piper Sandler retained to lead the process. See More Biotech Updates👇 $WINT $SRPT $RCKT $FOLD $MBRX $CLSD $ICU"
@BPharmCatalyst on X 2025-07-17 20:25:54 UTC 29.9K followers, 5636 engagements

"$PMN shares closed up after the company announced that PMN310 its lead therapeutic candidate for Alzheimer's received FDA Fast Track designation. See More Biotech Updates👇 $PMN $ZIMV $EVO $SABS $HOOK $SLRX $CLSD $GDTC"
@BPharmCatalyst on X 2025-07-21 20:58:48 UTC 29.9K followers, 2489 engagements

"$SRPT announced a strategic restructuring to prioritize high-impact programs ensure financial sustainability through 2027 and focus on siRNA platform opportunities. The plan includes $400M in annual cost savings and a XX% workforce reduction (500 employees) aiming for long-term growth and profitability. See More Biotech Updates👇 $APM $CUE $CYCC $NUWE $QLGN $RPTX $GANX $CGTX $IKNA"
@BPharmCatalyst on X 2025-07-16 20:29:56 UTC 29.9K followers, 6529 engagements

"$CLDI received FDA Fast Track designation for CLD-201 (SuperNova) its allogeneic adipose stem-cell loaded oncolytic virus for the treatment of soft tissue sarcoma. See More Pre-market Movers 👇 $DRRX $SCNI $SLRX $FULC $SRPT $APLS $NVO $ADAP $NEO"
@BPharmCatalyst on X 2025-07-29 12:21:06 UTC 29.9K followers, 4100 engagements

"BioPharmCatalyst Weekly #Watchlist Key Catalysts Due in Fall 2025 $ZYNE $ENTA $RLYB $KALA $ASMB $CAPR $RPTX $ASMB $XCUR"
@BPharmCatalyst on X 2025-07-25 20:38:54 UTC 29.9K followers, 5730 engagements

"$ANEB announced a proposed reverse stock split at a ratio between 1-for-2500 and 1-for-7500 as part of a plan to go private by reducing its number of shareholders. Stockholders with fewer than the minimum required shares post-split will be cashed out at $XXXX per pre-split share a XX% premium over the July XX 2025 closing price. The split is subject to stockholder approval and other conditions. See More Pre-market Movers 👇 $CLSD $IMNN $PHVS $IOVA $LTRN"
@BPharmCatalyst on X 2025-07-23 12:22:38 UTC 29.9K followers, 4377 engagements

"BioPharmCatalyst Weekly #Watchlist Key Catalysts Due in Fall 2025 $ZYNE $ENTA $RLYB $KALA $ASMB $CAPR $RPTX $ASMB $XCUR"
@BPharmCatalyst on X 2025-07-28 12:44:49 UTC 29.9K followers, 4929 engagements

"$ADAP will sell TECELRA lete-cel afami-cel and uza-cel to US WorldMeds for $55M upfront and up to $30M in milestones. US WorldMeds will handle commercialization and development while Adaptimmune focuses on preclinical programs (PRAME CD70 allogeneic) and will restructure. See More Biotech Updates👇 $CELC $ENTX $ADAP $ATHE $STXS $LYEL"
@BPharmCatalyst on X 2025-07-28 20:43:38 UTC 29.9K followers, 2105 engagements

"BioPharmCatalyst Weekly #Watchlist Key Catalysts Due in Mid-2025 $REPL $OTLK $RARE $WINT $ATAI $CYBN $IXHL $TNXP $VYNE $ATHE $PFE $CRDF $PRAX"
@BPharmCatalyst on X 2025-07-19 15:00:00 UTC 29.9K followers, 7406 engagements

"$REPL received a Complete Response Letter from the FDA for its BLA for RP1 with nivolumab in advanced melanoma citing the IGNYTE trial as inadequate due to patient heterogeneity and confirmatory trial design issues; no safety concerns were noted. Replimune plans to request a Type A meeting to discuss accelerated approval. See More Pre-market Movers 👇 $PMN $QNTM $STRO $GNLX $SPRC"
@BPharmCatalyst on X 2025-07-22 12:24:01 UTC 29.9K followers, 6677 engagements

"$GLPG reported that its first quarter 2025 results show consistent revenues of 140.3M but a significant XX% surge in R&D expenses to 278M. Overall expenses (G&A S&M) rose XX% to 74.5M. This led to a net loss of 259.1M a stark contrast to Q1 2024's 99.2M profit. Operating loss widened by XXX% to 215.7M. The company is exploring divestiture of its cell therapy business but maintains strong CAR-T programs and a solid 3.1B cash balance. See More Pre-market Movers 👇 $CYCC $PALI $ANNX $ATHE $MNOV $THAR $PSTV $ATRA $RCKT"
@BPharmCatalyst on X 2025-07-24 12:32:10 UTC 29.9K followers, 4389 engagements